Valneva SE Sponsored ADR (NASDAQ:VALN) Stock Short Interest Report for October

Valneva SE Sponsored ADR (NASDAQ:VALN) was the target of a large decline in short interest in October. As of October 30th, there was short interest totaling 47,986 shares, a decline of 75.0% from the October 15th total of 191,916 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average trading volume of 23,384 shares, the days-to-cover ratio is currently 2.1 days.

Valneva Stock Up 0.9%

Shares of Valneva stock opened at $5.92 on Thursday. Valneva has a 1 year low of $4.75 and a 1 year high of $12.18. The firm has a market cap of $563.52 million, a price-to-earnings ratio of -2.81 and a beta of 1.37. The company has a 50-day moving average of $6.02 and a 200 day moving average of $6.69. The company has a debt-to-equity ratio of 2.04, a current ratio of 2.16 and a quick ratio of 1.69.

Valneva (NASDAQ:VALN) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.21). The business had revenue of $39.37 million for the quarter, compared to the consensus estimate of $44.17 million. Valneva had a negative return on equity of 153.20% and a negative net margin of 110.33%. As a group, sell-side analysts anticipate that Valneva will post -1.27 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Weiss Ratings raised Valneva from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. TD Cowen initiated coverage on Valneva in a research report on Tuesday, August 11th. They set a “buy” rating and a $12.00 price target on the stock. One investment analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $9.30.

About Valneva

Valneva is a specialty vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases. Founded in 2013 through the combination of Vivalis and Intercell, the company is headquartered in Saint-Herblain, France, and serves markets in Europe, North America and other regions through direct operations and commercial partners. Its marketed vaccines include IXIARO, for prevention of Japanese encephalitis, and DUKORAL, an oral vaccine for cholera. Valneva also developed IXCHIQ, a vaccine to prevent disease caused by chikungunya virus, which has received regulatory authorization in the United States and Europe.